Epidemiology and Risk Factors of Uterine Fibroids in China
Launched by SHIXUAN WANG · Apr 21, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Epidemiology and Risk Factors of Uterine Fibroids in China" aims to understand how common uterine fibroids are among women in China, as well as what factors might lead to their development. Uterine fibroids are non-cancerous growths in the uterus that can sometimes cause symptoms, but many women may not have any noticeable signs. The study seeks to gather information about both women who experience symptoms and those who do not, to get a clearer picture of how often these fibroids occur and what might influence their growth.
To participate in this study, women aged 65 to 74 who have lived in their current location for at least six months and do not have serious mental health issues may be eligible. Participants will be asked to complete a questionnaire about their health and experiences with uterine fibroids. This research is important because it will help identify which women are more likely to develop fibroids and could lead to better understanding and management of this condition in the future. It's important to note that this trial is not yet recruiting participants, so there will be more information available later.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Current place of residence≥ 6 months;
- • No serious mental illness or mental abnormality;
- • Those who agree to participate in this survey and cooperate in completing the questionnaire.
- Exclusion Criteria:
- • -
About Shixuan Wang
Shixuan Wang is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization specializes in the design and execution of clinical studies across various therapeutic areas. Leveraging a robust network of experienced professionals and state-of-the-art methodologies, Shixuan Wang ensures the highest standards of regulatory compliance and ethical conduct in all its trials. The sponsor is driven by a mission to facilitate the development of groundbreaking therapies, ultimately contributing to the improvement of healthcare standards globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
SHIXUAN WANG, DOCTOR
Principal Investigator
Huazhong University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported